1.Bodnar, RJ, Hadjimarkou, MM. Endogenous opiates and behavior: 2001. Peptides. 2002;23:2307–2365.
2.Ribeiro, SC, Kennedy, SE, Smith, YR, Stohler, CS, Zubieta, JK. Interface of physical and emotional stress regulation through the endogenous opioid system and [mu]-opioid receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1264–1280.
3.Cross, AJ, Hille, C, Slater, P. Subtraction autoradiography of opiate receptor subtypes in human brain. Brain Res. 1987;418:343–348.
4.Frost, JJ, Wagner, HN, Dannals, RF, et al.Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomog. 1985;9:231–236.
5.Lever, JR. PET and SPECT imaging of the opioid system: receptors, radioligands and avenues for drug discovery and development. Curr Pharm Des. 2007;13:33–49.
6.Sugita, S, North, RA. Opioid actions on neurons of rat lateral amygdala in vitro. Brain Res. 1993;612:151–155.
7.Wiedenmayer, CP, Barr, GA. Mu opioid receptors in the ventrolateral periaqueductal gray medíate stress-induced analgesia but not immobility in rat pups. Behav Neurosci. 2000;114:125–136.
8.Liberzon, I, Zubieta, JK, Fig, LM, et al.mu-Opioid receptors and limbic responses to aversive emotional stimuli. Proc Natl Acad Sci U S A. 2002;99:7084–7089.
9.Zubieta, JK, Dannals, RF, Frost, JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry. 1999;156:842–848.
10.Apkarian, AV, Bushnell, MC, Treede, RD, Zubieta, JK. Human brain mechanisms of pain perception and regulation in health and disease. Euro J Pain. 2005;9:463–484.
11.Nelson, EE, Panksepp, J. Brain substrates of infant-mother attachment: contributions of opioids, oxytocin, and norepinephrine. Neurosci Biobehav Rev. 1998;22:437–452.
12.MacDonald, AW, Cohen, JD, Stenger, VA, Carter, CS. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science. 2000;288:1835–1838.
13.Sawamoto, N, Honda, M, Okada, T, et al.Expectation of pain enhances responses to nonpainful somatosensory stimulation in the anterior cingulate cortex and parietal operculum/posterior insula: an event-related functional magnetic resonance imaging study. J Neurosci. 2000;20:7438–7445.
14.Rainville, P, Duncan, GH, Price, DD, Carrier, B, Bushnell, MC. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science. 1997;277:968–971.
15.Eisenberger, NI, Lieberman, MD, Williams, KD. Does rejection hurt? An FMRI study of social exclusion. Science. 2003;302:290–292.
16.Panksepp, J. Feeling the pain of social loss. Science. 2003;302:237–239.
17.Schlaepfer, TE, Strain, EC, Greenberg, BD, et al.Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatry. 1998;155:470–473.
18.Leppa, M, Korvenoja, A, Carlson, S, et al.Acute opioid effects on human brain as revealed by functional magnetic resonance imaging. Neuroimage. 2006;31:661–669.
19.Becerra, L, Harter, K, Gonzalez, RG, Borsook, D. Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioidnaive healthy volunteers. Anesth Analg. 2006;103:208–216.
20.Petrovic, P, Kalso, E, Petersson, KM, Ingvar, M. Placebo and opioid analgesia–imaging a shared neuronal network. Science. 2002;295:1737–1740.
21.Shah, YB, Haynes, L, Prior, MJ, Marsden, CA, Morris, PG, Chapman, V. Functional magnetic resonance imaging studies of opioid receptor-mediated modulation of noxiousevoked BOLD contrast in rats. Psychopharmacology (Berl). 2005;180:761–773.
22.Wagner, KJ, Sprenger, T, Kochs, EF, Tölle, TR, Valet, M, Willoch, F. Imaging human cerebral pain modulation by dose-dependent opioid analgesia: a positron emission tomography activation study using remifentanil. Anesthesiology. 2007;106:548–556.
23.Zubieta, JK, Smith, YR, Bueller, JA, et al.Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science. 2001;293:311–315.
24.Kennedy, SE, Koeppe, RA, Young, EA, Zubieta, JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63:1199–1208.
25.Herman, BH. A possible role of proopiomelanocortin peptides in self-injurious behavior. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:S109–S139.
26.Liberzon, I, Taylor, SF, Phan, KL, et al.Altered central micro-opioid receptor binding after psychological trauma. Biol Psychiatry. 2007;61:1030–1038.
27.Ikeda, K, Ide, S, Han, W, Hayashida, M, Uhl, GR, Sora, I. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci. 2005;26:311–317.
28.Somogyi, AA, Barratt, DT, Coller, JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007;81:429–444.
29.Mayer, P, Höllt, V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics. 2006;16:1–7.
30.Arias, A, Feinn, R, Kranzler, HR, Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006;83:262–268.
31.Max, MB, Wu, T, Atlas, SJ, Edwards, RR, Haythornthwaite, JA, Bollettino, AF. A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. Mol Pain. 2006;2:14.
32.Stein, DJ, Newman, TK, Savitz, J, Ramesar, R. Warriors vs worriers: the role of COMT gene variants. CNS Spectr. 2006;11:745–748.
33.Zubieta, JK, Heitzeg, MM, Smith, YR, et al.COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240–1243.
34.Panksepp, J. Why does separation distress hurt? Comment on MacDonald and Leary (2005). Psychol Bull. 2005;131:224–230.
35.Panksepp, J, Panksepp, JB. The seven sins of evolutionary psychology. Evolution and Cognition. 2000;6:108–131.
36.Macdonald, G, Leary, MR. Why does social exclusion hurt? The relationship between social and physical pain. Psychol Bull. 2005;131:202–223.
37.Panksepp, J, Knutson, B, Burgdorf, J. The role of brain emotional systems in addictions: a neuro-evolutionary perspective and new ‘self-report’ animal model. Addiction. 2002;97:459–469.
38.Nesse, RM, Berridge, KC. Psychoactive drug use in evolutionary perspective. Science. 1997;278:63–66.
39.Gerald, MS, Higley, JD. Evolutionary underpinnings of excessive alcohol consumption. Addiction. 2002;97:415–425.
40.Kross, E, Egner, T, Ochsner, K, Hirsch, J, Downey, G. Neural dynamics of rejection sensitivity. J Cogn Neurosci. 2007;19:945–956.
41.Downey, G, Feldman, SI. Implications of rejection sensitivity for intimate relationships. J Pers Soc Psychol. 1996;70:1327–1343.
42.Panksepp, J. Affective Neuroscience: The Foundations of Human and Animal Emotions. New York, NY: Oxford University Press; 1998.
43.Schwartz, AC, Bradley, R, Penza, KM, et al.Pain medication use among patients with posttraumatic stress disorder. Psychosomatics. 2006;47:136–142.
44.Zacny, JRMorphine responses in humans: a retrospective analysis of sex differences. Drug Alcohol Depend. 2001;63:23–28.
45.Gowing, L, Ali, R, White, J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2006;(2):CD002025.
46.Amato, L, Davoli, M, A, Perucci C, Ferri, M, Faggiano, FP, Mattick, R. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28:321–329.
47.Boothby, LA, Doering, PL. Buprenorphine for the treatment of opioid dependence. Am J Health Syst Pharm. 2007;64:266–272.
48.Amato, L, Minozzi, S, Davoli, M, Vecchi, S, Ferri, M, Mayet, S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2004;(4):CD005031.
49.Amato, L, Minozzi, S, Davoli, M, Vecchi, S, Ferri, M, Mayet, S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2004;(4):CD004147.
50.Grant, JE, Kim, SW. Medication management of pathological gambling. Minn Med. 2006;89:44–48.
51.Srisurapanont, M, Jarusuraisin, N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2005;(1):CD001867.
52.Elchaar, GM, Maisch, NM, Augusto, LM, Wehring, HJ. Efficacy and safety of naltrexone use in pediatric patients with autistic disorder. Ann Pharmacother. 2006;40:1086–1095.
53.Symons, FJ, Thompson, A, Rodriquez, MC. Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis. Ment Retard Dev Disabil Res Rev. 2004;10:193–200.
54.Kosten, TR, Morgan, C, Kosten, TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990;7:51–54.
55.Gerra, G, Leonardi, C, D'Amore, A, et al.Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:265–272.
56.Emrich, HM, Vogt, P, Herz, A. Possible antidepressive effects of opioids: action of buprenorphine. Ann N Y Acad Sci. 1982;398:108–112.
57.Bodkin, JA, Zornberg, GL, Lukas, SE, Cole, JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15:49–57.
58.Saxe, G, Geary, M, Bedard, K, et al.Separation anxiety as a mediator between acute morphine administration and PTSD symptoms in injured children. Ann N Y Acad Sci. 2006;1071:41–45.
59.Bohus, MJ, Landwehrmeyer, GB, Stiglmayr, CE, Limberger, MF, Böhme, R, Schmahl, CG. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry. 1999;60:598–603.
60.Glover, H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci. 1993;30:255–263.
61.Lubin, G, Weizman, A, Shmushkevitz, M, Valevski, A. Short-term treatment of posttraumatic stress disorder with naltrexone: an open-label preliminary study. Hum Psychopharmacol. 2002;17:181–185.
62.Koran, LM, Aboujaoude, E, Bullock, KD, Franz, B, Gamel, N, Elliott, M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005;66:353–359.
63.Panksepp, J. Brain opioids: a neurochemical substrate for narcotic and social dependence. In: Cooper, SJ, ed. Progress in Theory in Psychopharmacology. London, England: Academic Press; 1981:149–175.
64.Panksepp, J, Herman, BH, Vilberg, T, Bishop, P, DeEskinazi, FG. Endogenous opioids and social behavior. Neurosci Biobehav Revs. 1980;4:473–487.